Abstract: A process and apparatus for removing hydrogen sulphide from a gas is disclosed. The process comprises the steps of: providing a gas comprising hydrogen sulphide; supplying oxygen for the process if the gas does not comprise oxygen, or does not comprise sufficient oxygen for converting hydrogen sulphide to elementary sulphur; leading the mixture of gas and, if supplied, oxygen to a tank comprising i) a foam forming liquid, such as a scrubber liquid and ii) a foam layer made from said foam forming liquid on the top of the foam forming liquid where the hydrogen sulphide in the gas is oxidized to elementary sulphur to form a cleaned gas removed from hydrogen sulphide.

Abstract: A process and apparatus for removing hydrogen sulphide from a gas is disclosed. The process comprises the steps of: providing a gas comprising hydrogen sulphide; supplying oxygen for the process if the gas does not comprise oxygen, or does not comprise sufficient oxygen for converting hydrogen sulphide to elementary sulphur; leading the mixture of gas and, if supplied, oxygen to a tank comprising i) a foam forming liquid, such as a scrubber liquid and ii) a foam layer made from said foam forming liquid on the top of the foam forming liquid where the hydrogen sulphide in the gas is oxidized to elementary sulphur to form a cleaned gas removed from hydrogen sulphide.

Abstract: The invention relates to growth hormone compounds with a long plasma half-life obtained by Fc linkage. An increased half-life is an advantage allowing a less frequent or low dosage administration of therapeutic. The invention further relates to methods of producing such compound including expression vectors for heterologous expression.

Abstract: The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation.

Abstract: The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.

Abstract: The present invention relates to growth hormone conjugates comprising a bile acid residue, said conjugation may occur through wt or mutant amino acid residues. The growth hormone polypeptide may be wt human growth hormone or a growth hormone variant.

Abstract: The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation.

Abstract: The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.

Abstract: The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

Abstract: The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.